This is from a couple of days back: Regeneron

This is from a couple of days back:

Quote:

---

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. Specifically, based on a potential safety signal and an unfavorable risk/benefit profile at this time, the IDMC recommends further enrollment of patients requiring high-flow oxygen or mechanical ventilation be placed on hold pending collection and analysis of further data on patients already enrolled. The IDMC also recommends continuing enrollment of hospitalized patients requiring either no or low-flow oxygen as the risk/benefit remains acceptable in these cohorts. Finally, the IDMC recommends continuation of the outpatient trial without modification.

---

So, it looks hat Regeneron is not effective in the S/C population ... There are very few drugs left out there trying to reduce death as a primary end-point.

Let me say this once more: we have "cojones". It is a very difficult end-point, but is the ultimate "prize". We are (and will be) saving lives that otherwise could not be saved by anybody else !!!!

We all should be proud and hopeful. Let the enrollment be swift so we all can have a good Christmas in terms of news of advancement of CD12.